SCHEMBL2856624

SCHEMBL2856624

N#Cc1ccc2oc(N3CCN(CCCCC(N)C(=O)N4CCSC4)CC3)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 10/20 0.54
DPP7 Q9UHL4 6/20 0.42
DPP8 Q6V1X1 2/20 0.42
DPP9 Q86TI2 2/20 0.42
PTGES O14684 1/20 0.41
DRD2 P14416 3/20 0.39
HTR1A P08908 2/20 0.39
ADRA2A P08913 2/20 0.39
ADRA2C P18825 2/20 0.39
SLC6A2 P23975 2/20 0.39
ADRA1D P25100 2/20 0.39
SLC6A4 P31645 2/20 0.39
HTR7 P34969 2/20 0.39
ADRA1A P35348 2/20 0.39
ADRA1B P35368 2/20 0.39
SLC6A3 Q01959 2/20 0.39
KCNH2 Q12809 2/20 0.39
ADRA2B P18089 1/20 0.39
DRD3 P35462 3/20 0.38
DRD4 P21917 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856619 1.00 DPP4 (0.54) DPP4DPP7DPP8DPP9PTGES
SCHEMBL2859695 0.86 DPP4 (0.44) DPP4DPP7DPP8DPP9
SCHEMBL2859690 0.86 DPP4 (0.44) DPP4DPP7DPP8DPP9
SCHEMBL2860339 0.86 DPP4 (0.50) DPP4DPP7DPP8DPP9DRD2
SCHEMBL2860343 0.86 DPP4 (0.50) DPP4DPP7DPP8DPP9DRD2
SCHEMBL2854274 0.86 DPP7 (0.42) DPP4DPP7DPP8DPP9DRD3
SCHEMBL2854270 0.86 DPP7 (0.42) DPP4DPP7DPP8DPP9DRD3
SCHEMBL2855991 0.83 DPP4 (0.46) DPP4DPP7DPP8DPP9DRD2
SCHEMBL2851844 0.83 DPP4 (0.54) DPP4DPP7DPP8DPP9HTR1A
SCHEMBL2851850 0.83 DPP4 (0.54) DPP4DPP7DPP8DPP9HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 DPP4 1/4885DPP7 2/4885DPP8 5/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 DPP4 1/4885DPP7 2/4885DPP8 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.